Compare Enbridge Inc (ENB) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Johnson & Johnson — how do they compare? Enbridge Inc trades at $51.6 (market cap $112.62B), while Johnson & Johnson trades at $260.7 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 5.6× Enbridge Inc's market cap, and Enbridge Inc pays the higher dividend (5.34%). Which is the better fit depends on your goals.
| ENB | JNJ | |
|---|---|---|
Market Cap | $112.62B | $626.09B |
Sector | Energy | Health |
52-Week High | $58.04 | $267.24 |
52-Week Low | $45.23 | $172.78 |
Enterprise Value | $196.53B | $654.37B |
Dividend Yield | 5.34% | 2.06% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $51.49, up 0.19% on the day, with a mixed technical picture showing bearish moving averages but oversold RSI levels. The company reported Q2 2026 EPS of $0.46, beating estimates of $0.43, and maintains a strong dividend yield with 31 consecutive years of increases. Revenue for 2025 reached $65.19B, with net income of $7.49B, though profit margins have fluctuated. Analyst consensus is evenly split between Buy and Hold ratings.
Outlook is stable with growth supported by a $41B project backlog and utility demand, but risks include regulatory challenges like pipeline disputes and high debt levels. The stock offers income appeal through dividends, yet faces headwinds from energy market volatility and legal uncertainties.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
